Skip to main content
Have a personal or library account? Click to login
Effects of teicoplanin on cell number of cultured cell lines Cover

Effects of teicoplanin on cell number of cultured cell lines

Open Access
|Dec 2015

References

  1. Bibler MR, Peter TF, Hagler DN, Bode RB, Staneck JL, Thamlikitkul V. (1987). Clinical evaluation of efficacy, pharmacokinetics, and safety of teicoplanin for serious Gram-positive infections.: 207–212.
  2. Eggleston M, Ofosu J. (1988). Teicoplanin, a new agent for gram positive bacterial infection.: 209–211.
  3. Glupezynski Y, Lagast H, Auwera PV, Thys JP, Crokaert F, Yourassowsky E, Meunier-Carpentier F, Klastersky J, Kains JP, Serruys-Schoutens E. (1986). Clinical evaluation of teicoplanin for therapy of severe infections caused by Gram positive bacteria.: 52–57.
  4. Guzek A, Korzeniewski K, Nitsch-Osuch A, Rybicki Z, Prokop E. (2013). In vitro susceptibility of staphylococci and enterococci to vancomycin and teicoplanin.: 125–132.
  5. Jovetic S, Zhu Y, Marcone GL, Marinelli F, Tramper J. (2010). β-Lactam and glycopeptide antibiotics: first and last line of defense?: 596–604.
  6. Matthews PC, Chue AL, Wyllie D, Barnett A, Isinkaye T, Jefferies L, Lovering A, Scarborough M. (2014). Increased teicoplanin doses are associated with improved serum levels but not drug toxicity.: 43–49.
  7. Oda K, Kasada T, Yoshikawa M, Tanoue M, Yamashita T, Takeshita Y. (2014). Therapeutic drug monitoring based on early measurements of serum teicoplanin levels in Japanese patients.(3): 401–405.
  8. Outman WR, Nightingale CH, Sweeney KR, Quintiliani R. (1990). Teicoplanin pharmacokinetics in healthy volunteers after administration of intravenous loading and maintenance doses.: 2114–2117.
  9. Salimi A, Talaie H, Rezaie Hemami M, Mahdavinejad A, Barari BB, Razi P, Kamalbeik S. (2014). Suggested Teicoplanin as an anti-methicillin resistant staphylococcus aureus agent in infections of severely poisoned intensive care unit patients.: 189–195.
  10. Somma S, Gastaldo L, Corti A. (1984). Teicoplanin, a new antibiotic from.: 917–923.
  11. Tobin CM, Lovering AM, Sweeney E, MacGowan AP. (2010). Analyses of teicoplanin concentrations from 1994 to 2006 from a UK assay service.: 2155–2157.
  12. Verbist L, Tijendramaga B, Hendrickx B, Hecken AV, Melle PV, Verbesselt R. (1984).activity and human pharmacokinetics of teicoplanin.: 881–886.
DOI: https://doi.org/10.1515/intox-2015-0004 | Journal eISSN: 1337-9569 | Journal ISSN: 1337-6853
Language: English
Page range: 22 - 24
Submitted on: Mar 16, 2015
Accepted on: Mar 26, 2015
Published on: Dec 10, 2015
Published by: Slovak Academy of Sciences, Institute of Experimental Pharmacology & Toxicology, Centre of Experimental Medicine
In partnership with: Paradigm Publishing Services

© 2015 Tahere Kashkolinejad-Koohi, Iraj Saadat, Mostafa Saadat, published by Slovak Academy of Sciences, Institute of Experimental Pharmacology & Toxicology, Centre of Experimental Medicine
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.